What are HCV NS3 protease inhibitor drugs?

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HCV NS3 protease inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting HCV NS3/4A serine protease). 0 are currently marketed, with 3 more in clinical development.

HCV NS3 protease inhibitor

0 marketed 3 in Phase 3

This page covers all HCV NS3 protease inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HCV NS3/4A serine protease.

Targets

HCV NS3/4A serine protease

Phase 3 pipeline (3)

BMS-650032 (Asunaprevir) · Bristol-Myers Squibb · Virology / Hepatology
Asunaprevir is a hepatitis C virus (HCV) NS3 protease inhibitor that blocks viral protein processing and replication.
Boceprevir (BOC) · Merck Sharp & Dohme LLC · Virology/Hepatology
Boceprevir is a hepatitis C virus (HCV) NS3 protease inhibitor that blocks viral protein processing and replication.
Cross-Over Boceprevir Treatment · Merck Sharp & Dohme LLC · Virology / Hepatology
Boceprevir is a hepatitis C virus (HCV) NS3 protease inhibitor that blocks viral replication by preventing the cleavage of HCV polyproteins.

Patent intelligence

hcv ns3 protease inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates